Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose azathioprine plus allopurinol vs azathioprine in inflammatory bowel disease
2013-001503-37Phase 3Completed
- Sponsor
- Marianne Kiszka-Kanowitz
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease comparing Conventional azathioprine with Low-dose azathioprine plus allopurinol (2 arms). Primary endpoint: Clinical remission at weeks 8, 12, and 24. Started May 2013; status: completed.
02
Drugs
azathioprineallopurinol
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2013-001503-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001503-37.